WO2004078951A1 - ラクトナーゼの製法およびその利用 - Google Patents
ラクトナーゼの製法およびその利用 Download PDFInfo
- Publication number
- WO2004078951A1 WO2004078951A1 PCT/JP2004/002643 JP2004002643W WO2004078951A1 WO 2004078951 A1 WO2004078951 A1 WO 2004078951A1 JP 2004002643 W JP2004002643 W JP 2004002643W WO 2004078951 A1 WO2004078951 A1 WO 2004078951A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lactonase
- producing
- transformant
- sequence
- recombinant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
- C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/02—Oxygen as only ring hetero atoms
- C12P17/04—Oxygen as only ring hetero atoms containing a five-membered hetero ring, e.g. griseofulvin, vitamin C
Definitions
- the present invention relates to a method for producing a lactonase having D-pantolactone hydrolase activity.
- the present invention relates to the expression and secretory production of lactase having D-pantolactone hydrolase activity in microorganisms.
- the present invention also relates to a method for producing the optically active ⁇ -lactone and its related compounds using the enzyme and a system for producing the enzyme.
- D-pantolactone is known as an intermediate in the production of D-pantothenic acid, D-panthenol, and pantethine. These are useful as medically or physiologically important vitamins, as pharmaceuticals, food additives, feed additives, and cosmetic ingredients.
- D pantolactone is produced by optically resolving chemically synthesized D and leptolactone.
- this method requires expensive resolving agents such as quinine and pulsin, and has drawbacks such as difficulty in recovering D-pantolactone.
- the present inventors have presented the optical resolution method by enzymatic asymmetric hydrolysis of D, L pantolactone in Patent Document 1 and Patent Document 2.
- Patent Document 3 International publication pamphlet ffO, A, 97/10341 Disclosure of the invention
- the enzyme produced by a transformant obtained using Escherichia coli or the like has no sugar chain added, has a smaller molecular weight than the natural type (wild type), and lacks stability. Was required.
- An object of the present invention is to produce a system for efficiently producing an enzyme using natural lactonase gene and having excellent productivity. Further, the present invention further provides an optical activity that is more efficient and more productive by using the enzyme and a system for producing the enzyme. '-In building a lactone production system.
- D-pantolactone hydrolase (hereinafter referred to as "lactonase") having D-pantolactone hydrolase activity, especially lactonase cloned and identified from Fusarium oxysporum, is results of the analysis of Yadenko includes five intron: 53 by chromosomal gene consisting of the base pairs are co one de, enzyme twenty Ryo consisting amino acid residue NH 2 -terminal signal base peptide
- the mature enzyme encoded by cMA complementary to mMA transcribed from the chromosomal gene is a protein consisting of 380 amino acids.
- wild type is the one with a sugar chain added.
- the present inventors have conducted intensive studies to develop a system in which a sugar chain is added even to a recombinant enzyme, and as a result, a gene sequence encoding the lactonase gene with a signal peptide
- the enzyme was introduced into a host cell and expressed, whereby large-scale expression of the enzyme to which a natural type sugar chain was added was successful, and the present invention was completed.
- the signal peptide region is an amino acid sequence consisting of the -20th to 11th amino acids of SEQ ID NO: 9 or a partial sequence thereof, or an Alp signal peptide region;
- a lactonase-producing transformant according to any one of [1] to [4] above is cultured to produce recombinant lactonase, and the obtained recombinant lactonase is obtained.
- R 1 and B 2 are the same or different and each independently represents hydrogen or a lower alkyl group.
- a lactonase-producing transformant which has been introduced with lactonase having D-pantolactone hydrolase activity and DNA encoding a signal peptide region, or a vector into which the lactase has been inserted;
- the vector is characterized in that one or more of the Enhancer sequences on the Aspergillus oryzae darcosidase gene (agdA) motor are introduced into a promoter region that functions in filamentous fungi.
- the lactonase-producing transformant according to any one of the above [1] to [4] and [7] to [9];
- the vector has a marker gene suitable for selecting a transformant of a host filamentous fungus, has a terminator, has a DM region capable of replicating in Escherichia coli, and has a polypeptide in a filamentous fungus.
- the lactonase-producing transformant according to any one of the above [7] to [12], which is an expression plasmid;
- the nitrile reductase gene derived from a filamentous fungus The lactonase-producing transformant of the above-mentioned [13], which is a translase gene, a tryptophan synthase gene, or an acetoamidase gene;
- signal peptide region is an amino acid sequence comprising the -20th to 11th amino acids of SEQ ID NO: 9 in the sequence listing or a Fusarium filamentous fungus Alp signal peptide region.
- R represents a hydroxyl group or an amino group
- R 1 and ⁇ 2 are the same or different and each independently represents hydrogen or a lower alkyl group.
- a salt thereof according to the above [1] to [4] and a culture of the lactonase-producing transformant according to any one of [7] to [24], a cell thereof, a cell processed product thereof, or an immobilized bacterial cell, or a recombinant obtained from the transformant Contacting with a member selected from the group consisting of lactone and immobilized recombinant lactonase, unreacted general formula (II)
- R represents a hydroxyl group or an amino group
- R 1 and R 2 are the same or different and each independently represents hydrogen or a lower alkyl group.
- R, R 1 and R 2 are the same as defined above, or a salt thereof, which is represented by the general formula (IV)
- a DM comprising a sequence encoding a lactonase and a signal peptide region
- the present invention provides a method comprising:
- the lactonase-producing transformant according to any one of (1) to (4), (7) to (24), (30), and (31) is immobilized. Immobilized cells;
- the recombinant lactonase obtained from the lactonase-producing transformant according to any one of [1] to [7, [7] to [24], [30], and [31] is immobilized.
- the invention relates to
- the invention's effect Selected from the group consisting of cultures of lactonase-producing transformants, their cells, cell-treated products, or immobilized cells, recombinant lactonase obtained from the transformants, and immobilized recombinant lactonase Or the use of the MA according to any one of the above [27] to [29].
- the present invention provides a technology for utilizing a natural lactonase gene to produce a system for producing the enzyme efficiently and with excellent productivity.
- the present invention enables the construction of an optically active 7-lactone production system that is efficient and more productive using the enzyme and a system that produces the enzyme.
- an expensive resolving agent is not required, and it is suitable for industrial production with a simple operation, has no environmental problems, is useful as a pharmaceutical intermediate in an efficient manner, and is useful for amino acids and pantothenic acid.
- Optically active 7-lactone derivatives as starting materials can be produced.
- a method for easily and industrially producing an optically active ⁇ -lactone derivative is provided.
- D-pantolactone and its derivatives for example, pantothenic acid, calcium pantothenate, panthenol, pantethine, coenzyme A (CoA), pantothenyleethyl ether, pantethine or a salt thereof are efficiently and economically excellent. Can be manufactured.
- FIG. 1 shows an electrophoresis photograph of the result of examining the expression of a foreign lactonase gene in A. oryzae.
- Lane 1 shows a gel stained with Coomassie Brilliant Blue for proteins separated by electrophoresis.
- Lane 1 has molecular weight (Daiichi Chemicals, Tokyo, Japan): phosphorylase b (97 kDa), pericyserum albumin (66 ld) a), aldolase U2 kDa), and carbonic anhydrase (30 kDa) ) 0
- Lane 2 is Serufuri one extract of A. oryzae transformed with pMN_PC
- Lane 3 is Serufuri one extract of A. oryzae transformed with PMN XG. 25, u is applied to each Lane.
- Lane 4 is purified lactonase obtained from F. oxysporum. 0.5 is applied.
- Lane 1 is a molecular g marker iprestained SDS-PAGE standards low range, Bio-ad, Hercules, USA J: Phosphorylase b (97 kDa), Pserum serum albumin (66 kDa), ovalbumin (45 kDa), carbonic Anhydrase (31 kDa), trypsin inhibitor (22 kDa).
- Figure 2 shows the asymmetric hydrolysis of racemic pantolactone using F. oxysporum and recombinant A. oryzae. The result of decomposition is shown.
- A shows the results using the wet cells
- B shows the results using the immobilized cells.
- White circles are A. oryzae transformed with pNAN-PC, black circles are / L oryzae transformed with pMN-XG, and white squares are F. oxysporum.
- FIG. 3 shows the structure of a plasmid for secretion expression of lactonase.
- the fusion gene was constructed by combining PCE, cut with Sal I and Xbal, and subcloned into Bluescript II SK +.
- FIG. 4 shows an electrophoresis (SDS-PAGE) photograph of lactonase secreted by an Ac. Chrysogenum transformant. Uses 10% polyacrylamide gel.
- Lane 1 was purified wild-type lactonase obtained from F. oxysporum (0.5, Lane 2 was Ac. Chrysogenum (containing 3 g protein) transformed with pAlpS, Lane 3 was transformed with pLacS
- Lane 4 shows the molecular weight markers: phosphorylase b (97 ld) a), Pseudoplasmic serum alpmin (66 kDa octaldolase (42 kDa), and carbonic acid). Hydraulase (30 kDa) 0
- FIG. 5 shows an electrophoresis (SDS-PAGE) photograph of lactonase that has been subjected to sugar chain cleavage.
- Purified recombinant lactonase (Lane 8-11) from Ac. Chrysogenum transformed with wild-type lactonase (Lane 2-5) and pAlpS was treated with EndoH £ and treated with 10% polylactone. It was electrophoresed on an acrylamide gel (0.8 g per lane).
- Lane 2 and Lane 8 are for 1 minute sugar chain cleavage
- Lane 3 and Lane 9 are for 5 minute sugar chain cleavage
- Lane 4 and Lane 10 are for 15 minute sugar chain cleavage
- Lane 5 and Lane 11 Is a sugar chain cleavage treatment for 60 minutes.
- Lane 1 and Lane 7 show the wild-type lactonase and the recombinant lactonase that have not been subjected to glycolytic cleavage.
- Lane 6 is a mole
- FIG. 6 shows the results of asymmetric hydrolysis of racemic pantolactone by the immobilized enzyme.
- the ratio of D- and pantoic acid was determined by HPLC. Black circles indicate D-pantoic acid, white circles indicate L-pantoic acid, and white squares indicate DL-pantolactone (racemic pantolactone).
- FIG. 7 shows the nucleotide sequence of chromosomal DNA (genomic gene) encoding a lactase derived from a filamentous fungus of the genus Fusarium.
- the sequence of the 20 amino acid residues at the NH 2 -terminal (base sequence of 1 to 60) is shaded in the signal peptide region.
- the five introns are shown in lower case letters, the predicted N-glycosylated asparagine residues are diamond-marked, and the relevant stop codons are shown with an asterisk. .
- a lactonase enzyme having a natural D-pantolactone hydrolytic activity for example, a wild-type (natural) lactonase derived from Fusarium oxysporum ( ⁇ pantolactone hydrolase) or an activity substantially equivalent thereto
- the present invention provides a recombinant expression technology of a gene encoding a protein having Preparation, culture and propagation of host cells transformed with MA containing the base sequence encoding the lactonase, production of the protein using the host cell, and further uses of the protein and the host cell.
- the present invention provides various useful means utilizing the gene encoding the above lactonase.
- D-pantolactone which is more efficient and more productive is provided.
- a production system is provided.
- the present invention D, L-Pantoraku in tons D - relates Raku Tonaze characterized by having a body selectively asymmetric hydrolysis allowed to activity, click ⁇ Ra contain NH 2 -terminal signal peptide region Tonaze
- the resulting transformant When transformed using a gene encoding the full length, the resulting transformant not only expresses and produces a recombinant enzyme having a molecular weight almost equal to the wild-type enzyme, but also has a stable enzyme activity.
- the technology utilizes knowledge that is satisfactory in the field of lactonase. By using recombinant technology, it is possible to obtain transformed cells that retain higher catalytic activity and stable enzyme activity.
- the present invention provides a technique for expression and secretory production of lactonase having activity as a D-pantolactone hydrolase in a microorganism.
- a gene encoding the full length lactonase
- the gene is introduced into a filamentous fungus, for example, a bacterium such as Aspergillus or Acremonium, in a form containing an N-terminal signal peptide region, the resulting transformant is added with a sugar chain having the same molecular weight as the wild-type enzyme.
- the enzyme has better enzyme stability than an enzyme that does not undergo glycosylation, and furthermore, the transformant A.
- the oryzae strain also improved the hydrolysis rate compared to Fusarium oxysporum.
- Ac. Chrysogenum platform ratatonase can be secreted in large amounts outside the cells, and DL-pantolactone hydrolysis at the enzyme level (crude, purified or immobilized enzyme) is possible.
- the gene recombination technology used in the present invention is described in, for example, T.
- the PCK method involves repeating a cycle of performing primer extension synthesis using two oligonucleotide primers that can preferentially hybridize with a type I nucleic acid.
- a primer complementary to the nucleotide sequence to be amplified inside Type I can be used.
- Those that are complementary at both ends or adjacent to the nucleotide sequence to be amplified can be preferably used.
- the 5'-end primer should contain at least a start codon, or be selected so that it can be amplified including the start codon, and the 3'-end primer contains at least a stop codon Alternatively, it is preferable to select so as to enable amplification including the stop codon.
- Primers include oligonucleotides consisting of preferably 5 or more bases, more preferably 10 or more bases, more preferably: oligonucleotides consisting of 18 to 25 bases.
- the PCR reaction can be performed by a method known in the art or a method substantially similar to or a modification thereof.
- a method known in the art for example, R. Saiki, et al., Science, 230: 1350, 1985; R. Saiki, et. , Science, 239: 487, 1988; HA Erlich ed., PCR Technology, Stockton Press, 1989; DM Glover et al. ed., "MA Cloning", 2nd ed., Vol. Approach Series), IRL Press, Oxford University Press (1995); MA Innis et al. Ed., "PCR Protocols: a guide to methods and applications", Academic Press, New York (1990)); MJ McPherson, P.
- PCR a practical approach, IEL Press, Oxford (.1991); MA Frohman et al., Proc. Natl. Acad. Sci. USA, 85, 8998-9002 (1988), etc.
- the method can be carried out according to the method described in, or by modifying or modifying the method.
- the PCR method can be performed using a commercially available kit suitable for the PCR, and can also be performed according to a protocol specified by a kit manufacturer or kit distributor.
- ⁇ oligonucleotide J '' is a relatively short single-stranded or double-stranded polynucleotide, preferably a polydeoxynucleotide, and Angew. Chem. Int. Ed. , Vol. 28, p. 716-734 (1989), such as the phosphotriester method, the phosphodiester method, the phosphite method, the phosphoramidite 'method, the phosphoramidite method, and the like. It can be chemically synthesized by a method such as the phonate method, etc. Usually, it is known that synthesis can be conveniently performed on a modified solid support.
- the oligonucleotide may contain one or more modified bases, such as those commonly found in nature such as inosine. It may contain no bases or tritylated bases, and in some cases, may contain a base with a marker.
- a hybridization technique may be used. The hybridization can be performed by the method described in the literature that discloses the above-mentioned “gene recombination technique”, or a method substantially similar to or a modification thereof.
- Hydride is a method in which a sample containing nucleic acid such as MA is transferred to a carrier including a membrane such as a nylon filter, and then subjected to denaturation treatment, immobilization treatment, washing treatment, etc. as necessary.
- the reaction is carried out by reacting the DNA transcribed on the carrier (for example, a membrane) with a denatured labeled probe DNA fragment, if necessary, in a hybridization buffer.
- the hybridization process is usually performed at about 35 to about 80 ° C, more preferably about 50 to about 65 ° C, for about 15 minutes to about 36 hours, more preferably about 1 to about 24 hours.
- the optimal conditions can be selected appropriately.
- the hybridization treatment is performed at about 55 ° C. for about 18 hours.
- the buffer for the hybridization can be selected from those commonly used in this field, and for example, Kapid hybridization buffer (Amersham) or the like can be used.
- Examples of denaturation treatment of the transferred carrier include a method using an alkali denaturing solution, and after the treatment, treatment with a neutralizing solution or a buffer is preferable.
- the immobilization treatment of the carrier is usually performed at about 40 to about 100, more preferably at about 70 to about 90 ° C, for about 15 minutes to about 24 hours, more preferably at about 1 hour. It is carried out by baking for about 4 hours, but it can be carried out by appropriately selecting preferable conditions. For example, immobilization is performed by baking a carrier such as a filter at about 80 ° C for about 2 hours.
- Washing of the transferred carrier includes washing solutions commonly used in the art, for example, 50 mM Ti'is-HC1 containing 1 M NaCl, ImM EDTA and 0.1% sodium dodecyl sulfate (SDS). It can be performed by washing with a buffer solution, pH 8.0 or the like.
- the carrier including the membrane such as a nylon filter can be selected from those commonly used in this field.
- alkali denaturing solution, neutralizing solution and buffer solution those commonly used in the art can be selected and used. Examples of the alkali denaturing solution include 0.5M NaOH and 1.5M NaCl.
- the neutralizing solution includes, for example, a 1.5 M NaCl-containing 0.5 M Tris-HCl buffer, pH 8.0, and the like.
- X SSPE (0. 36M NaCl, 20mM NaH 2 P0 4 and 2 ⁇ EDTA) and the like.
- the transferred carrier for example, a membrane
- a prehybridization treatment if necessary, in order to prevent a nonspecific hybridization reaction.
- This pre-hybridization treatment is performed, for example, using a pre-hybridization solution [50% formamide, 5 x Denhardfs solution (0.2% ⁇ serum alumin, 0.2% polyvinyl pyrrolidone), 5 x SSPE, 0.1% SDS ⁇ 100 ⁇ g / ml heat-denatured salmon sperm A], etc., at about 35 to about 50 ° C, preferably about 42 ° C, for about 4 to about 24 hours, preferably about 6
- the reaction can be carried out for about 8 hours, but such conditions can be determined by those skilled in the art by repeating appropriate experiments.
- the denaturation of the NA fragment may be carried out, for example, by heating at about 70 to about 100 ° C, preferably about 100 ° C, for about 1 to about 60 minutes, preferably for about 5 minutes. Can be done.
- the high The blidization can be carried out by a method known per se or a method analogous thereto.
- the stringent condition is, for example, about 15 to about 50 mM, preferably about 19 to About 40 mM, more preferably about 19 to about 20 mM, and the temperature is about 35 to about 85 ° C, preferably about 50 to about 70 ° C, more preferably about 60 to about 65 ° C.
- the washing treatment of the carrier such as a filter can be performed by selecting from those commonly used in the field, for example, 0.1% SDS containing 0.5 X SSC (0.15M NaCl, It can be carried out by washing with a solution.
- the hybridized nucleic acid can be typically detected by autoradiography, but can be appropriately selected from methods used in the art and used for the detection.
- a suitable buffer for example, SM solution (lOOmM NaCl and 10 mM MgSO 4 containing 50 mM Tris-HCl buffer, pH 7. 5) was suspended in like, then moderate the suspension
- SM solution lOOmM NaCl and 10 mM MgSO 4 containing 50 mM Tris-HCl buffer, pH 7.5
- the desired nucleic acid can be isolated, purified, and subjected to further amplification.
- the screening of the target nucleic acid from the nucleic acid sample including the gene library and the cDNA library by the hybridization treatment can be performed repeatedly.
- the lactonase used in the present invention is, for example, Fusarium sp. Genus Ndrocarbone, Gibberella, Aspergillus, Penicillium, Rhizopus, Volterra, Gliocladium, Eurotium, Nectoria, Schizophyllum, Mio Cesium, Neirosbora, Acremonium Or a microorganism belonging to the genus Tuberculina, the genus Absizia, the genus Sporostrix, the genus Verti-Silium or the genus Arsloderma.
- Representative examples include, for example, Fusarium oxysporum IF0 5942, Fusarium-Semictatum IF0 30200, Silindrocarbon Tonkinens IF0 30561, Zipperella fuzicroi IF0 6349, Aspergillus oryzae ATCC 91002, Alpergillus olisperifos Chrysogenum IF0 4266, Rhizopus oryzae IF0 4706, Volterra Buxi IF0 6003, Gliocladium 'force tenuratam IF0 6121, ⁇ urotim' Chevalier IF0 4334, Nexus 0187. Komune IF0 4928, MI ROCESIUM.
- the gene encoding the lactonase used in the present invention can be obtained by using a gene recombination technique according to TO, A, 97/10341; Proc. Natl. Acad. Sci. USA, 95, 12787-92, 1998. Can be obtained.
- the cultured Fusarium oxysporum cells are disrupted, the chromosome DM is centrifuged by a conventional method, A is decomposed and removed, and the protein is removed to purify the MA component.
- the whole ENA was extracted from the disrupted cells according to the method, and then purified using an appropriate method, for example, using an oligo dT cellulose column to purify ml-NA.
- CDNA may be synthesized using a transcriptase (reverse transcriptase) or the like.
- it can be obtained by the PCE method and the reverse transcription PCR (polymerase chain reaction coupled reverse transcription; RT-PCR) method using an already constructed gene library and an appropriate primer. It can also be obtained by using the already obtained lactone gene as a probe. Labeling of a probe or the like with a radioisotope can be performed using a commercially available labeling kit, for example, a random prime MA labeling kit (Boehringer Mannheim).
- random - priming kit (Pharmacia LKB, Inc., Uppsala) using such an MA probe [a - 3 2 P] dCTP (Amersham Co.) was labeled with a, it is possible to obtain a probe with radioactivity.
- a phage particle, a recombinant plasmid, a recombinant vector, etc. having a predetermined nucleic acid can be purified and separated by a method commonly used in the relevant field. For example, glycerol gradient ultracentrifugation It can be purified by a separation method (Molecular Cloning, a laboratory manual, ed. T. Maniatis, Cold Spring Harbor Laboratory, 2nd ed.
- the DM in the manner commonly used in the art can isolate made fine, for example, resulting phage TM solution (10 mM MgSO 4 containing 50 mM T ris-HCl buffer, pH 7 8), treat with Mase I and RNase A, add 20mM EDTA, 50 ⁇ g / ml Proteinase and 0.5,% 'SDS mixed solution, etc., about 65 ° C ⁇ about 1 hour After keeping it warm, it was extracted with phenol and extracted with getyl ether, and precipitated by ethanol precipitation. Then, the obtained DM was washed with 70% ethanol and dried, and then TE solution (10 mM EDTA containing 10 mM EDTA) was added.
- the desired DM can also be obtained in large quantities by subcloning or the like.
- subcloning can be performed using Escherichia coli as a host and a plasmid vector.
- DM obtained by such subcloning can be purified and separated by methods such as centrifugation, phenol extraction, and ethanol precipitation in the same manner as described above.
- the nucleotide sequence can be determined using the Didoxy method, for example, the MaxanrGilbert method, such as the M13 Didoxy method, but a commercially available sequencing kit, for example, a Taq die primer cycle sequencing kit, etc. Or an automatic base sequencer, for example, a fluorescent DM sequencer.
- a nucleic acid is a nucleic acid such as a single-stranded DM, a double-stranded A, RNA, DNA: RNA hybrid, or synthetic DNA, and a genomic M (chromosomal gene MA), genomic
- the DNA may be any of a DNA library, cDM, and synthetic MA.
- the base sequence of the nucleic acid can be modified (eg, added, removed, substituted, etc.), and such modifications can be included.
- the nucleic acid may encode the peptide described in the present invention or a part thereof, and preferred is DNA. Nucleic acids can also be obtained by chemical synthesis. In such a case, the fragments may be chemically synthesized and ligated with an enzyme.
- the obtained nucleic acid such as a PCR product (including MA) is usually cut out from the gel as a specific band by subjecting the gel to gel electrophoresis, for example, gene clean kit (Bio101). Extract using a commercially available extraction kit such as).
- the extracted DM is cleaved with an appropriate restriction enzyme, purified if necessary, and further, if necessary, phosphorylated at the 5 'end with T4 polynucleotide kinase, etc., and then pUC-based such as pUC18.
- Ligation into a suitable plasmid vector, such as a vector is used to transform suitable competent cells.
- the cloned PCR product may be analyzed for its nucleotide sequence.
- Plasmid vectors can be used.
- Plasmid vectors calcium method, rubidium / calcium method, calcium / manganese method, high-efficiency TFB method, FSB freezing cell method, rapid colony method, It can be carried out by a method known in the art such as electroporation or a method substantially similar thereto. Hanahan, J. Mol. Biol., 166: 557, 1983).
- a codon suitable for expression in a selected host cell can be introduced, or a restriction enzyme site can be provided.
- control sequences and facilitating sequences to facilitate expression of the target gene It can control linkers, adapters, etc., as well as antibiotic resistance and metabolism, and can contain sequences useful for selection and the like.
- Plasmid vectors suitable for expression in E. coli also include pAS, pKK223 (Pharmacia), pMC1403, pMC931, pKC30, and the like.
- the host cell in the case of Escherichia coli, for example, those derived from Escherichia coli K12 strain can be mentioned.
- a restriction enzyme, reverse transcriptase, or an enzyme for modifying or converting a DM fragment into a structure suitable for cloning is known or widely used in the art.
- Certain DM modification / degrading enzymes, DM polymerase, terminal nucleotidyltransferase, DNA ligase, and the like can be used.
- the lactase may be expressed as a fusion protein and converted and processed into a substance having substantially the same biological activity as the wild-type enzyme in vivo or in vitro. .
- a fusion production method commonly used in genetic engineering can be used, and such a fusion protein can be purified by affinity chromatography using the fusion portion.
- Modification and alteration of the protein structure should be performed by methods widely known in the art, such as by using site-directed mutagenesis (site-directed mutagenesis) using synthetic oligonucleotides, etc., or by using PCBs. Can be.
- a DM encoding the lactonase and the signal peptide is constructed and suitably used to prepare a transformant expressing the lactonase.
- the MA encoding the lactose a MA derived from a filamentous fungus of the genus Fusarium can be suitably used. It shall recombinant Lac Tonaze expression nucleotide sequence for utilization in the present invention, for example having a DM sequence NH 2 -terminal signal peptide region co one de the A array and the ease Tonaze encoding easy Tonaze full length .
- recombinant easy Tonaze expression for nucleotide sequences (a) Fusarium fungi from La click toner Ichize cMA sequence or chromosomal gene encoding the full length]) NH 2 terminal signal base peptide of M sequence and the Lac Tonaze It may contain a MA sequence encoding the region.
- the sequence having the Fusarium-derived filamentous lactase and a sequence encoding a signal peptide region can be incorporated into an appropriate expression vector.
- Examples of the expression vector include one having one or more of the Enhansa mononucleotide sequence of a filamentous fungus, and a promoter for expression of an alkaline protease (Alp) produced by a filamentous fungus of the genus Fusarium (FusariuDi).
- Alpha alkaline protease
- One having a single region one having one or more of the Enhansa single nucleotide sequence of a filamentous fungus introduced into a region of a promoter that functions in the filamentous fungus, and a signal peptide region having a signal sequence region related to secretion of the Alp or the same.
- Those that can be configured to be a signal sequence region of tonase are included.
- Expression vectors suitable for expression in filamentous fungi include those having an enhancer sequence on the ⁇ -glucosidase gene (agdA) promoter of Aspergillus oryzae and a promoter region.
- the promoter for introducing the enhancer sequence is not particularly limited as long as it functions in a filamentous fungus. Specific examples thereof include ⁇ -amylase, glucoamylase, ⁇ -glucosidase, and protease.
- Suitable promoters can be isolated from Aspergillus ⁇ -amylase, glucoamylase, and ⁇ -darcosidase genes. More preferably, the promoter of the ⁇ -glucosidase gene of Aspergillus oryzae is used.
- an expression plasmid that can be suitably used in the present invention includes a promoter that functions in an improved filamentous fungus as described above, and a terminator, which is suitable for selection of a host transformant. It has a single gene and a DM region that can be replicated in E. coli.
- the introduction site of the promoter of the enhancer sequence is not particularly limited as long as it is a promoter region.
- the evening terminator is not particularly limited as long as it functions in a filamentous fungus.
- a terminator of Aspergillus oryzae-glucosidase gene or a terminator containing a partial sequence thereof is more preferably used.
- Preferred selection markers include the genes for nitrate reductase (niaD), orditin rubamoyltransferase (argB), tryptophan synthase (trp, acetate amidase (amdS)).
- a suitable selection marker gene is the nitrate reductase gene (niaD), which expresses the present invention using a restriction enzyme recognition site provided between the promoter and terminator.
- a DNA fragment encoding the desired protein to be used is introduced.
- expression vectors suitable for use include those disclosed in, for example, JP-A-09-9968 and JP-A-5-268972.
- plasmids pNLH2, pNAN8142, etc. can be preferably used.
- synthetic MA may be used as the adapter DNA, and any synthetic MA may be used as long as the frames of both genes match and the activity of the gene of interest is not lost.
- Expression of the target gene using thease gene promoter and the translation initiation site and a no or secretion signal is performed by preparing a fusion gene so that the frame of the target gene matches the site of the target gene.
- the target substance can be secreted and produced outside the cells, as long as the function of the promoter is not lost. May delete some of the DM fragments, and may alter the function of the promoter and translation initiation site, eg, For example, even if the DNA base sequence of the region including the promoter and the translation initiation site is modified so that the expression power is increased, it can be conveniently used, and the region not related to the functions of the promoter and the translation initiation site can be used.
- the host for introducing the target gene constructed as described above can be used as long as the organism operates and expresses the gene.
- a representative host may be appropriately selected from eukaryotes such as yeasts, filamentous fungi, and plants.
- eukaryotes such as yeasts, filamentous fungi, and plants.
- Representative examples include, for example, Fusarium Oxysporum IF0 5942, Fusarium Semitectum IF0 30200, Cylindrocarbon Tonkinens IF0 30561, Giperera phujikuroi IF0 6349, Aspergillus oryzae ATCC 91002, Alpergillus sulzer 5 Armory IF0 4033, Penicillium Krysogenum IF04626, Rhizopus Oryzae IF04706, Volterra Buxi IF0 6003, Gliocladium 'Catenumratum IF0 6121, Eurotium Shevalier IF0 4334, Nexus 0 G7 Lam Komune IF0 4928, Milosecium Mouth Redam IF0 9531, Neurosbora Classa IF0 6067, Acremonium Fucidioides IF06813, Hubbell Clinna Persicina IF0 6464, Absizia Rihisei Mi IF0 4009,
- any organism can be used as long as the gene operates and expresses.
- it is appropriately selected from eukaryotic microorganisms such as yeasts and filamentous fungi.
- yeast include bacteria of the genus Saccharomyces, genus Schizosaccharomyces, and genus Pichia.
- +)-calomyces Selechi-> (.Saccharomyces cerevisiaeJ ⁇ Schizosaccharomyces pombe, Pichia pastoris (Pichia pastoris), etc.
- the filamentous fungi include the genus Acremonium, Aspergillus sperg Genus, Fusarium genus, Penicillium genus, Mucor genus, Neurospora genus, Trichoderma genus and the like.
- Transformation methods for introducing a gene into these hosts include, for example, protoplast transformation method, etc.
- protoplast cells prepared using an appropriate cell wall lysing enzyme can be used to transform In the presence of calcium chloride, polyethylene dalicol, etc.
- Transformation can be performed by, for example, contacting with M. Transformation methods include the electoral poration method (for example, E. Neumann et al.). al., " ⁇ ⁇ , Vol. 1, pp. 841 (1982), etc.) Microphone port Print We transfection method, and a method of implanting a gene gun.
- the fusion gene may be inserted into a plasmid having a gene for an appropriate selection marker that functions in the host, and then the host may be transformed with the plasmid.
- Any gene can be used as the selectable marker-transmitting gene as long as it can selectively separate transformed cells. Typical examples include a hygromycin B resistance gene.
- the host must use a strain that does not have a functional gene for the selected selection force.
- Various conditions for culturing the transformed cells obtained by the present invention vary depending on the type of cells such as the strain used, but generally, as for the medium, the transformed cells are assimilated or assimilated. A medium containing a carbon source, a nitrogen source, and the like that can be used.
- the carbon source may be any as long as the transformed cell can assimilate or assimilate the cells, for example, glucose, sucrose, starch, soluble starch, dextrin, etc. Saccharides, paraffins, etc., and organic acids such as acetic acid, citric acid, butyric acid, fumaric acid, and benzoic acid; alcohol amounts such as methanol, ethanol, butanol, and glycerin; oleic acid; and stearic acid. And their esters, and oils and fats such as soybean oil, rapeseed oil, lard oil and the like, and these can be used alone or in combination.
- ammonium salts such as ammonium sulfate and ammonium nitrate, nitrates such as sodium nitrate and potassium nitrate, urea, peptone, and casamino.
- Acid corn stay Corn gluten meal, bran, yeast extract, dried yeast, soybean flour, cottonseed flour, meat extract, other organic or inorganic nitrogen-containing substances, etc., which can be used alone or in combination .
- Nutrients such as inorganic salts, minerals, vitamins, and trace metal salts can be optionally added to the medium.
- inorganic salts examples include magnesium sulfate, sodium chloride, calcium carbonate, phosphates such as potassium hydrogen phosphate and potassium hydrogen phosphate, and manganese salts. Extracts and the like are also included. In addition, those commonly used in the relevant field can be appropriately selected and used.
- the culture time is usually about 1 to 20 days, preferably about 3 to 14 days, and more preferably about 3 to 14 days. In about 10 days, the culture is performed at pH 3-9 of the medium, at the culture temperature of 10-50 ° C.
- Enzymes produced by the transformed cells obtained in the present invention can be obtained from various known materials, for example, enzyme-producing materials such as transformed cells, including cell culture solutions and cell culture crushed products, by methods known in the art. Can be obtained according to For example, when accumulated in a medium, a supernatant containing the target substance is obtained by centrifugation or filtration.
- the target substance accumulates in cells such as bacterial cells
- the cells are collected by a known method such as centrifugation or filtration, and the cells are buffered with a protein denaturant such as guanidine hydrochloride. Suspended in a liquid, stirred in a cold place, and then centrifuged to obtain a supernatant containing the target protein, or after suspending the cells in a buffer, pulverizing with glass beads, French pressing, ultrasonic waves
- a method in which cells are disrupted by treatment or enzyme treatment, and then a supernatant is obtained by centrifugation or the like is used as appropriate.
- the target protein can be separated and purified from the supernatant by appropriately combining known separation and purification methods, for example, salting-out such as ammonium sulfate precipitation, or solvent such as using ethanol.
- Precipitation method, gel filtration method using Sephadex, etc. for example, ion-exchange chromatography method using a carrier having a basic or acidic group such as getylaminoethyl group or carboxymethyl group, for example, butyl group, octyl group, phenyl group, etc.
- solubilization treatment for example, treatment with a denaturing agent such as guanidine hydrochloride or urea and, if necessary, a reducing agent such as 2-mercaptoethanol or dithiothreitol It can also be used as an active enzyme.
- a denaturing agent such as guanidine hydrochloride or urea
- a reducing agent such as 2-mercaptoethanol or dithiothreitol
- an enzyme-producing cell can be used as it is.
- the immobilized enzyme include those in which an enzyme or an enzyme-producing cell is immobilized by a method known in the art. .
- immobilization of microbial cells on an alginate gel can also be suitably used.
- a condensing agent such as glutaraldehyde, hexamethylene diisothiocyanate, or hexamethylene diisothiocyanate can be used and immobilized as necessary.
- a monomer method in which a monomer is gelled by a polymerization reaction a prepolymer method in which a molecule larger than a normal monomer is polymerized, a polymer method in which a polymer is gelated, and the like, are exemplified. Immobilization using natural polymers such as alginic acid, collagen, gelatin, agar, and Ichiragi ginnan, immobilization using synthetic polymers such as photocurable resins and urethane polymers And the like.
- transformants cultured with shaking in a liquid medium are collected, and an aqueous solution of D, L-pantractone (2 to 60% concentration) is added to the obtained cells, and the temperature is adjusted to 6 to 8 while adjusting the pH to 6 to 8. Incubate at 10-40 ° C for several hours to one day. After completion of the reaction, the cells are separated, and unreacted L pantratatone in the reaction solution is converted into an organic solvent (esters such as ethyl acetate, aromatic hydrocarbons such as benzene, and halogenated compounds such as chloroform). (Preferably hydrocarbons and the like).
- the D-pantoic acid remaining in the aqueous layer is lactonized by heating under acidic hydrochloric acid, and is produced by extraction with the above organic solvent! )-You can get Pantoracton.
- a compound of the general formula (I) or a salt thereof is prepared by introducing a lactonase derived from a filamentous fungus belonging to the genus Fusarium and a lactonase into which DM encoding a signal peptide region or a vector into which the vector is inserted.
- the transformant obtained as described above, in particular, the transformed microorganism is preferably used to selectively asymmetrically hydrolyze the compound of the general formula (I) in the R form.
- it can be represented by the following reaction formula.
- R represents a hydroxyl group or an amino group
- E 1 and E 2 are the same or different, and each independently represents hydrogen or a lower alkyl group.
- Examples of the lower alkyl group of E 1 and R 2 include linear or branched alkyl groups having 1 to 5 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, t -Butyl group and the like.
- R is a hydroxyl group and U 1 and E 2 are both methyl groups, in which case the racemic pantolactone of the general formula (I) or a salt thereof is Active pantolactone or a salt thereof, for example, D-pantolactone or a salt thereof of the general formula (IV), or L-pantolactone or a salt thereof of the general formula (II) can be produced.
- the transformant to be used in particular, the transformed microorganism is treated with a culture obtained by culturing the strain in a liquid medium, a cell isolated from the culture solution, or a cell or culture. Any form such as a dried cell obtained by the above method or an immobilized cell can be used.
- the enzyme isolated from the transformant may be a crude or purified enzyme, Any form such as a fixed one can be used.
- the operation can be batch, semi-batch, or continuous.
- the concentration of single rat used is usually between 10 and 500 g / L.
- the reaction temperature is usually from 10 to 50 ° C, but is more preferably from 20 to 30 ° C.
- the reaction time is usually several hours to one day for a batch system.
- the pH of the reaction system is usually about 3 to 9, but is more preferably 6 to 8.
- the inorganic salt for maintaining the pH a hydroxide or a carbonate of an alkali metal or an alkaline earth metal, as well as ammonia water and the like are used.
- Organic solvents include halogenated hydrocarbons such as ethylene chloride, chloroform, and trichloroethane, aromatic hydrocarbons such as benzene and toluene, ethers such as getyl ether, and 1-butylmethyl ether.
- halogenated hydrocarbons such as ethylene chloride, chloroform, and trichloroethane
- aromatic hydrocarbons such as benzene and toluene
- ethers such as getyl ether
- 1-butylmethyl ether 1-butylmethyl ether.
- ethyl acetate or the like is used, and more preferably, ethyl acetate.
- Separation methods other than extraction include column chromatography and the like. It is also possible to separate the compound of the general formula (II) from the compound of the general formula (II) with water, an alcohol such as methanol or ethanol, or a mixture thereof, using a reversed phase column. It is.
- the compound of the general formula (III) remaining in the reaction solution can be converted into the compound of the general formula (IV) by making it acidic as it is.
- As the acid hydrochloric acid, sulfuric acid or the like is used, and sulfuric acid is more preferable.
- the pH, the reaction temperature, and the reaction time may be set so that the compound of the general formula ( ⁇ ) can be converted into the compound of the general formula ( ⁇ ) by ring closure, but more preferably, the pH is 1 or more.
- the reaction temperature is 80-130 and the reaction time is 1-6 hours.
- the resulting compound of the general formula (IV) is recovered by extraction with an organic solvent.
- the organic solvent used here is the same as the solvent used for the extraction of the compound of the general formula (II), as well as halogenated hydrocarbons such as ethylene chloride, chloroform and trichloroethane, benzene and toluene.
- halogenated hydrocarbons such as ethylene chloride, chloroform and trichloroethane, benzene and toluene.
- aromatic hydrocarbons such as acetylene
- ethers such as dimethyl ether and t-butyl methyl ether, ethyl acetate and the like are used, and more preferably ethyl acetate. Recovery by column chromatography is also possible.
- the compound of the general formula (II) remaining in the reaction solution is treated with an alkali metal hydroxide or carbonate, the reaction solution is distilled off under reduced pressure, and the dried product is recrystallized with a solvent. By doing so, it can be isolated as a metal salt of carboxylic acid.
- hydroxides or carbonates of alkali metal used include lithium hydroxide, sodium hydroxide, sodium hydroxide, lithium carbonate, sodium carbonate, carbonated carbonate, and the like.
- sodium hydroxide is used. It is.
- methanol, ethanol, isopropanol, chloroform, and the like are used, and preferably, methanol is used.
- D-pantolactone having high optical purity can be obtained in high yield.
- D-pantolactone can be condensed with a Ca salt or ester of alanine in an alcoholic solvent to obtain calcium D-pantothenate.
- D-pantolactone can be obtained in an organic solvent such as alcohol.
- Condensed with alanine or its ester to form D-pantothenic acid After that, a method of reacting calcium compounds such as calcium carbonate (E. Stiller, et al., J. Am. Chem.
- D-pantolactone is reacted with a-aminopropionitrile in an organic solvent such as alcohol to give D-pantothenitrile, and further added with cysteamine, and reacted to give 2- (2-D-pantoamidoethyl) -2.
- -Thiazoline then hydrolyzed to D-pantethine, and then condensed in the presence of hydrogen peroxide to produce pantethine (M, Shimizu, et al., Chem. ⁇ harm. Bull., 13, 180 U965)).
- D-pantothenic acid and / or a salt thereof, or D-panthenol can be efficiently obtained.
- the present invention provides a simple and efficient method for producing an optically active arractone derivative useful as a pharmaceutical intermediate diamino acid derivative.
- the terms are based on the meaning of the terms according to the IUPAC-IUB Commission on Biochemical Nomenclature or as commonly used in the art. The meanings of typical terms are shown below.
- Cystine N Asparagine (Asn)
- G Glycine (Gly) S: Serine (Ser)
- Aspergillus oryzae A. oryza e / pNAN-XG transformed with pNAN-XG described in Example 1 described below, 1-1-1 Tsukuba-Higashi, Ibaraki Prefecture since February 4, 2003 1 Chuo 6 (AIST Tsukuba Central 6, 1-1, Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken 305-8566 Japan, former address notation: 1-3-1, Higashi Tsukuba, Ibaraki Prefecture) (Postal code 305) -8566) National Institute of Advanced Industrial Science and Technology, International Patent Organism Depositary (IP0D) (former name: Ministry of Economy, Trade and Industry) Research Institute (NIBH)) and deposited (Accession No.
- IP0D International Patent Organism Depositary
- Plasmid PFLC40E containing mature lactonase cDNA derived from Fusarium oxysporum (containing no N-terminal signal peptide and intron) was treated with the restriction enzymes EcoM and Xbal to isolate a fragment containing the lactone cDNA. After blunting this, the expression plasmid pNAN8142 (Japanese Patent Application Laid-Open No. 09-9968, Biosci. Biotec nol. Biochem., 60: 383-389, 1996) was transferred to the PmaCI site downstream of the ⁇ - ⁇ 8142 promoter. And obtained pNAN-PC.
- pNAN-XC introduced the sequence of the cMA and signal peptide of the lactonase gene, and was constructed as follows.
- the whole was extracted from F. oxysporum by the AGPC method (method using phenol and guanidine thiocyanate) (kit name: IS0GEN, Futatsubon Gene).
- AGPC method method using phenol and guanidine thiocyanate
- a 1.3 kb MA fragment was amplified using the RT-PCR (a method of amplifying DNA from ENA using PCR) [Access RT-PCR System; Promega].
- Two oligonucleotides, FusLacl (with Xhol cleavage sequence underlined) and FusLac2 (with Xbal cleavage sequence underlined) were used as primers.
- PCR width conditions were in accordance with the instruction manual of the above kit.
- the PCR product was purified by low melting point agarose gel, cut with restriction enzymes Xhol and Xbal, and then inserted into the same cleavage site of plasmid: PNAN8142.
- the full-length lactonase gene on the genome was amplified from all DM of F. oxysporum using PCR with FusLacl and FusLac 2 as primers.
- the amplified MA fragment is composed of the restriction enzymes Xhol and Xbal After cleavage with, plasmid: inserted into the similar cleavage site of PMN8142, this was designated as pMN-XG
- the above plasmids were individually transformed into Aspergi llus oryzae (ATCC91002) and Aspergi llus oryzae niaD mutant AON-2 paco prepared by Unkles SE et al. (Mol. Gen. Genet. 218, 99-104, 1989). Lactonase activity was measured.
- the method for measuring lactonase activity is as follows.
- Transformants of pNAN-XG showed the highest lactonase activity (approximately 7.4 times that of F.030!), and NAN-XC also showed equivalent activity. In the body, the activity was one-fourth that of pMN-XG (Table 1).
- the signal peptide Since only the pNAN_PC transformant without the addition of the signal peptide region produced a deglycosylated enzyme, the signal peptide is located in the ER where transglycosylation occurs after translation. It was considered necessary to be transported.
- F. oxysporum and A. oryzae transformants (CpNAN-PC and pMN-XG) were reacted with a 35% DL-pantolactone solution while controlling the pH to 6.8 to 7.5.
- the initial reaction rate was high, but the stability of the enzyme was poor, and the reaction hardly progressed after 2 hours.
- the hydrolysis rate of DL-pantolactone was 8.523 ⁇ 4, which was lower than 14.6% of F. oxysporum (Fig. 2A).
- the enzyme of the pNAN-XG transformant is pN It was more stable than the enzyme of the AN-PC transformant and the hydrolysis rate was 19.8 19 ..
- the transformant was suspended in 1% sodium alginate and dropped into a 2% calcium chloride solution to immobilize the transformant.
- the stability of both pNM-XG and pNM-PC transformants was improved, and the hydrolysis rate of DL-pantolactone was significantly improved.
- the optical purity was 953 ⁇ 4e.e. Or higher.
- the Alp promoter followed by the Alp signal peptide and propeptide were amplified by PCE using plasmid pNLH 2 (Japanese Patent Application Laid-Open No. 5-268972) as type III.
- the primers used are as follows.
- Sense primer AlpPS (The underlined part is the synthesized Sail cleavage sequence)
- Antisense primer AlpPA (underlined part anneals to a part of LacS primer).
- LacS 5'-CATCAGCATCAACATGGCTAA6CTAAGCTTCCTTCTACG6CTC-3 '(SEQ ID NO: 5)
- the lactonase gene without the N-terminal signal peptide can be obtained by using ⁇ X-XG as a ⁇ type and using sense primer LacS (the underlined part anneals with a part of the AlpPA primer) and antisense primer FusLac2 (SEQ ID NO: 2). Amplified by PCR. Each PCB product was mixed, and the second PCE was performed using AlpPS and FusLac2 as primers. The obtained PCE fragment (2.3 kb) was cut with Sall and Xbal and introduced into pBluescript to construct lpS.
- pLacS places the signal peptide of lactonase itself under the control of the Alp promoter and was also constructed using Combined PCE.
- the Alp promoter was amplified by PCR using the primers AlpPS and AlpPA2 (underlined part anneals to a part of the LacS2 primer), and the full-length gene having the signal peptide of lactonase itself was primer LacS2; (The underlined part can be annealed with a part of the AlpAP2 primer.) Amplification was performed by PCR using the primer FusLac2.
- a I pPA2 5'-T6GAAGAAGGCATCTT6TCAGGGAGTATGAAGGTTG-3 '[SEQ ID NO: 6]'
- LacS2 5'-TACTCCCTGACAAGATGCCTTCTTCCTTTCTGTA-3 '(SEQ ID NO: 7)
- the above plasmids were individually transformed into Ac. Chrysogenum (ATCC11550).
- the genomic MA of the transformant was designated as a prominent type, and the oligonucleotides at the 3 'and 5' end regions of the lactonase gene were used as primers.
- PCE analysis was performed. When the PCB product was subjected to agarose gel electrophoresis, a 1.2 kb band corresponding to the lactonase gene was detected in about 80% of the 80 transformants tested.
- Each transformant was pre-cultured at 28 ° C for 3 days in a medium containing 30 g Sucrose, 5 g DL-methionine, 32 g soy bean Hour, 1.5 g calcium carbonate (pH 6.8) per liter, and further cultured in 500 mL medium.
- Main culture was performed at 28 ° C for 5 days at 120 strokes / min. Lactonase activity of the culture supernatant was measured. Lactonase activity was determined by reacting 0.5 mL of a reaction solution containing 0.5 M Tris-HCl buffer (pH 7.4), 0.61 mM (80 mg) D-pantolactone and an appropriate amount of enzyme at 30 ° C for 15 minutes.
- pantolactone and pantoic acid in the reaction solution were analyzed by HPLC. As a result, a large amount of lactonase was observed in the culture supernatant of the transformants of pAlpS and pLacS (Table 2).
- end glycosidase that cleaves high mannose and hybrid oligosaccharides derived from N-linked glycoprotein was isolated from F. oxysporum and pAlpS transformants, respectively. After reacting with the purified enzyme for 1, 5, 15, and 60 minutes, SDS-PAGE was performed. Three different molecular weight bands of 60, 56, and 51 kDa were detected ( Figure 5), indicating that they had at least two N-linked glycosides.
- the enzyme immobilized resin (15 g) and 35 mL (w / v) DL-pantolactone (75 mL) were reacted at 30 ° C. while maintaining the pH at 6.8 to 7.5 with gentle stirring. Asymmetric hydrolysis proceeded efficiently, and no by-product L-pantoic acid was detected (Fig. 6).
- the hydrolysis rate increased to 40%, that is, the hydrolysis rate of the D-form increased to 80%, and reached 24% after 24 hours.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Botany (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2004217677A AU2004217677B2 (en) | 2003-03-03 | 2004-03-03 | Process for producing lactonase and utilization thereof |
BRPI0407947-7A BRPI0407947A (pt) | 2003-03-03 | 2004-03-03 | transformante produtor de lactonase, processos para a produção de uma lactonase recombinante com atividade de enzima que hidrolisa a d-pantolactona, para a produção de um derivado de gama-lactona opticamente ativa e para a produção de um derivado de d-pantolactona ou sal desde, e, uso de um membro ou de um dna |
EP04716788A EP1600499B1 (en) | 2003-03-03 | 2004-03-03 | Process for producing lactonase and utilization thereof |
DE602004022639T DE602004022639D1 (de) | 2003-03-03 | 2004-03-03 | Verfahren zur herstellung von lactonase und nutzung davon |
CA002518402A CA2518402A1 (en) | 2003-03-03 | 2004-03-03 | Process for producing lactonase and utilization thereof |
AT04716788T ATE440131T1 (de) | 2003-03-03 | 2004-03-03 | Verfahren zur herstellung von lactonase und nutzung davon |
US10/547,424 US20070134775A1 (en) | 2003-03-03 | 2004-03-03 | Process for producing lactonase and utilization thereof |
JP2005503072A JPWO2004078951A1 (ja) | 2003-03-03 | 2004-03-03 | ラクトナーゼの製法およびその利用 |
US12/232,870 US20090137012A1 (en) | 2003-03-03 | 2008-09-25 | Process for producing lactonase and utilitzation thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-55233 | 2003-03-03 | ||
JP2003055233 | 2003-03-03 | ||
JP2003371750 | 2003-10-31 | ||
JP2003-371750 | 2003-10-31 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/232,870 Division US20090137012A1 (en) | 2003-03-03 | 2008-09-25 | Process for producing lactonase and utilitzation thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004078951A1 true WO2004078951A1 (ja) | 2004-09-16 |
Family
ID=32964870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/002643 WO2004078951A1 (ja) | 2003-03-03 | 2004-03-03 | ラクトナーゼの製法およびその利用 |
Country Status (11)
Country | Link |
---|---|
US (2) | US20070134775A1 (ja) |
EP (1) | EP1600499B1 (ja) |
JP (1) | JPWO2004078951A1 (ja) |
KR (1) | KR20050109950A (ja) |
CN (1) | CN100402640C (ja) |
AT (1) | ATE440131T1 (ja) |
AU (1) | AU2004217677B2 (ja) |
BR (1) | BRPI0407947A (ja) |
CA (1) | CA2518402A1 (ja) |
DE (1) | DE602004022639D1 (ja) |
WO (1) | WO2004078951A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011105344A1 (ja) * | 2010-02-23 | 2011-09-01 | 東レ株式会社 | カダベリンの製造方法 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101448950B (zh) * | 2006-05-16 | 2014-02-12 | 帝斯曼知识产权资产管理有限公司 | 用于生产泛醇的工艺 |
CN107628963B (zh) * | 2017-10-16 | 2020-08-04 | 宁夏金维制药股份有限公司 | 一种维生素b5粗品的制备方法 |
CN108191688A (zh) * | 2017-12-28 | 2018-06-22 | 大连韦德生化科技有限公司 | 一种合成及结晶d-泛酸钙的方法 |
CN110452861B (zh) * | 2019-07-10 | 2021-02-09 | 杭州师范大学 | 一种基因重组工程菌及其在催化合成d-泛酰内酯中的应用 |
CN112774251A (zh) * | 2019-11-27 | 2021-05-11 | 安徽华恒生物科技股份有限公司 | 酸与酯混合溶液的分离方法 |
CN112175919B (zh) * | 2020-09-30 | 2024-02-09 | 江西兄弟医药有限公司 | 内酯水解酶突变体及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0365198A (ja) | 1989-08-03 | 1991-03-20 | Fuji Yakuhin Kogyo Kk | D―パントラクトンの製造法 |
JPH04144681A (ja) | 1990-10-05 | 1992-05-19 | Fuji Yakuhin Kogyo Kk | D―パントラクトン加水分解酵素およびその製造法 |
EP0519229A2 (en) * | 1991-05-22 | 1992-12-23 | Takeda Chemical Industries, Ltd. | Alkaline protease gene from fusarium sp |
WO1997010341A1 (fr) | 1995-09-13 | 1997-03-20 | Fuji Yakuhin Kogyo Kabushiki Kaisha | D-pantolactone hydrolase et gene codant ladite substance |
WO2002074926A2 (en) * | 2001-03-19 | 2002-09-26 | Cargill Incorporated | Myo-inositol oxygenases |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6395529B1 (en) * | 1998-11-10 | 2002-05-28 | Novozymes Biotech, Inc. | Polypeptides having lactonohydrolase activity and nucleic acids encoding same |
JP2003512015A (ja) * | 1998-11-10 | 2003-04-02 | ノボザイムス バイオテック,インコーポレイティド | ラクトノヒドロラーゼ活性を有するポリペプチド及びそれをコードする核酸 |
-
2004
- 2004-03-03 WO PCT/JP2004/002643 patent/WO2004078951A1/ja active Application Filing
- 2004-03-03 CA CA002518402A patent/CA2518402A1/en not_active Abandoned
- 2004-03-03 AT AT04716788T patent/ATE440131T1/de not_active IP Right Cessation
- 2004-03-03 BR BRPI0407947-7A patent/BRPI0407947A/pt not_active IP Right Cessation
- 2004-03-03 CN CNB2004800075765A patent/CN100402640C/zh not_active Expired - Fee Related
- 2004-03-03 JP JP2005503072A patent/JPWO2004078951A1/ja active Pending
- 2004-03-03 EP EP04716788A patent/EP1600499B1/en not_active Expired - Lifetime
- 2004-03-03 US US10/547,424 patent/US20070134775A1/en not_active Abandoned
- 2004-03-03 KR KR1020057016198A patent/KR20050109950A/ko not_active Application Discontinuation
- 2004-03-03 DE DE602004022639T patent/DE602004022639D1/de not_active Expired - Lifetime
- 2004-03-03 AU AU2004217677A patent/AU2004217677B2/en not_active Ceased
-
2008
- 2008-09-25 US US12/232,870 patent/US20090137012A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0365198A (ja) | 1989-08-03 | 1991-03-20 | Fuji Yakuhin Kogyo Kk | D―パントラクトンの製造法 |
JPH04144681A (ja) | 1990-10-05 | 1992-05-19 | Fuji Yakuhin Kogyo Kk | D―パントラクトン加水分解酵素およびその製造法 |
EP0519229A2 (en) * | 1991-05-22 | 1992-12-23 | Takeda Chemical Industries, Ltd. | Alkaline protease gene from fusarium sp |
WO1997010341A1 (fr) | 1995-09-13 | 1997-03-20 | Fuji Yakuhin Kogyo Kabushiki Kaisha | D-pantolactone hydrolase et gene codant ladite substance |
EP0794251A1 (en) * | 1995-09-13 | 1997-09-10 | Fuji Yakuhin Kogyo Kabushiki Kaisha | D-pantolactone hydrolase and gene encoding the same |
WO2002074926A2 (en) * | 2001-03-19 | 2002-09-26 | Cargill Incorporated | Myo-inositol oxygenases |
Non-Patent Citations (2)
Title |
---|
ALBERTS BRUCE ET AL.: "Essential saibo seibutsugaku", KAIBUSHIKI KAISHA NANKODO, 15 February 1999 (1999-02-15), pages 467 - 470, XP002904681 * |
KOBAYASHI M. ET AL.: "Lactone-ring-cleaving enzyme: Genetic analysis, novel RNA editing, and evolutionary implications", PROC. NATL. ACAD. SCI. USA, vol. 95, 1998, USA, pages 12787 - 12792, XP002134265 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011105344A1 (ja) * | 2010-02-23 | 2011-09-01 | 東レ株式会社 | カダベリンの製造方法 |
US8871477B2 (en) | 2010-02-23 | 2014-10-28 | Toray Industries, Inc. | Process for production of cadaverine |
JP5853695B2 (ja) * | 2010-02-23 | 2016-02-09 | 東レ株式会社 | カダベリンの製造方法 |
Also Published As
Publication number | Publication date |
---|---|
BRPI0407947A (pt) | 2006-03-07 |
CA2518402A1 (en) | 2004-09-16 |
ATE440131T1 (de) | 2009-09-15 |
US20090137012A1 (en) | 2009-05-28 |
EP1600499B1 (en) | 2009-08-19 |
JPWO2004078951A1 (ja) | 2006-06-08 |
DE602004022639D1 (de) | 2009-10-01 |
EP1600499A4 (en) | 2006-08-30 |
US20070134775A1 (en) | 2007-06-14 |
EP1600499A1 (en) | 2005-11-30 |
AU2004217677A1 (en) | 2004-09-16 |
AU2004217677B2 (en) | 2008-09-11 |
CN100402640C (zh) | 2008-07-16 |
KR20050109950A (ko) | 2005-11-22 |
CN1761742A (zh) | 2006-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002301052B2 (en) | Lipase/Acyltransferase | |
US7247463B2 (en) | Enzymes with lipase/acyltransferase activity, nucleic acids encoding the same and methods of use thereof | |
US20090137012A1 (en) | Process for producing lactonase and utilitzation thereof | |
CN105802951B (zh) | 固定化脂肪酶及其制备方法和用途 | |
JPH10508475A (ja) | トリペプチジルアミノペプチダーゼ | |
CN108251400B (zh) | 脂肪酶及其应用 | |
US20100196970A1 (en) | Butynol I esterase | |
KR101749429B1 (ko) | 올레산 수화효소 유전자, 상기 유전자를 함유한 발현벡터, 및 상기 발현벡터로 형질전환된 형질전환체 | |
WO2019155790A1 (ja) | ランダムエステル交換リパーゼ | |
EP2478098A1 (en) | Preparation of beta-amino acids | |
CN111088240B (zh) | 一种酯酶及其编码基因和应用 | |
Ghasemian et al. | Production of recombinant microbial thermostable lipases | |
CN109943618B (zh) | 一种重组脂肪酶在拆分(R,S)-α-乙基-2-氧-1-吡咯烷乙酸甲酯中的应用 | |
US20050112644A1 (en) | Thermostable hydrolase | |
EP1966373B1 (en) | Polypeptide having esterase activity and recombinant esterase and use thereof | |
JP2010187658A (ja) | D−フェニルセリンデアミナーゼ及びその利用 | |
JP2009291158A (ja) | ピリドキサミン−ピルビン酸アミノトランスフェラーゼの変異酵素 | |
KR102097720B1 (ko) | 마리노박터 리포리티쿠스 유래 지질분해효소 | |
CN115960872A (zh) | 一种角蛋白酶及其编码基因以及用于制备角蛋白水解物的应用 | |
JP4397088B2 (ja) | 還元酵素をコードする遺伝子 | |
JP2004313033A (ja) | 新規なカルボニル還元酵素及びそれをコードする遺伝子並びにその用途 | |
Bae et al. | Molecular cloning and characterization of a novel cold-active lipase from Pichia lynferdii NRRL Y-7723 | |
KR20160042254A (ko) | 피키아 파스토리스 균주를 이용한 캔디다 앤탁티카 균주 유래 리파제의 생산방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004716788 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004217677 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057016198 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2518402 Country of ref document: CA Ref document number: 2005503072 Country of ref document: JP Ref document number: 2105/CHENP/2005 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2004217677 Country of ref document: AU Date of ref document: 20040303 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004217677 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048075765 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057016198 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004716788 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0407947 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007134775 Country of ref document: US Ref document number: 10547424 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10547424 Country of ref document: US |